Starzl T E, Marchioro T L, Zühlkek V, Brettschneider L
Med Times. 1967 Feb;95(2):196-208.
Progress in homotransplantation of the kidney has been reviewed. This form of therapy for the patient with terminal uremia has resulted in a 2-year survival of more than 50% at the University of Colorado Medical Center, excluding from consideration identical twin cases. The best results were with the use of kidneys obtained from familial donors; when this has been possible the 2-year survival is almost /. With randomly selected non-related living donors the 2-year survival was only 22%. Although these results indicate the great potential value of organ transplantation, the techniques being employed today are imperfect. The need for progress with better immunosuppression, better histocompatibility analysis, and better organ preservation are outlined.
肾同种移植的进展已被综述。在科罗拉多大学医学中心,这种针对终末期尿毒症患者的治疗方式已使不包括同卵双胞胎病例在内的患者2年生存率超过50%。使用来自亲属供体的肾脏效果最佳;若能做到这一点,2年生存率几乎为/。使用随机选择的非亲属活体供体时,2年生存率仅为22%。尽管这些结果表明器官移植具有巨大的潜在价值,但目前所采用的技术并不完美。文中概述了在更好的免疫抑制、更好的组织相容性分析以及更好的器官保存方面取得进展的必要性。